{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T00:28:50Z","timestamp":1794702530923,"version":"4.9.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,2]]},"DOI":"10.1093\/rheumatology\/40.2.178","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:37:51Z","timestamp":1027723071000},"page":"178-184","source":"Crossref","is-referenced-by-count":110,"title":["Prevalence and spectrum of rheumatic diseases associated with proteinase 3\u2010antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase\u2010ANCA"],"prefix":"10.1093","volume":"40","author":[{"given":"U.","family":"Sch\u00f6nermarck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lamprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Csernok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. L.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2001,2]]},"reference":[{"key":"key\n\t\t\t\t20170703111748_R1","unstructured":"Gross WL, Csernok E. Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis. Curr Opin Rheumatol1995;7:11\u20139."},{"key":"key\n\t\t\t\t20170703111748_R2","doi-asserted-by":"crossref","unstructured":"Bajema IM, Hagen EC. Evolving concepts of antineutrophil cytoplasm autoantibodies in systemic vasculitides. Curr Opin Rheumatol1999;11:34\u201340.","DOI":"10.1097\/00002281-199901000-00006"},{"key":"key\n\t\t\t\t20170703111748_R3","doi-asserted-by":"crossref","unstructured":"Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int1998;53:796\u20138.","DOI":"10.1038\/ki.1998.36"},{"key":"key\n\t\t\t\t20170703111748_R4","unstructured":"Davenport A, Lock RJ, Wallington TB, Feest TG. Clinical significance of anti\u2010neutrophil cytoplasm antibodies detected by a standardized indirect immunofluorescence assay. Q J Med1994;87:291\u20139."},{"key":"key\n\t\t\t\t20170703111748_R5","doi-asserted-by":"crossref","unstructured":"Edgar JD, McMillan SA, Bruce IN, Conlan SK. An audit of ANCA in routine clinical practice. Postgrad Med J1995;71:605\u201312.","DOI":"10.1136\/pgmj.71.840.605"},{"key":"key\n\t\t\t\t20170703111748_R6","doi-asserted-by":"crossref","unstructured":"Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of antineutrophil cytoplasmic antibody (c\u2010ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta\u2010analysis. Ann Intern Med1995;123:925\u201332.","DOI":"10.7326\/0003-4819-123-12-199512150-00005"},{"key":"key\n\t\t\t\t20170703111748_R7","doi-asserted-by":"crossref","unstructured":"Rao JK, Allen NB, Feussner JR, Weinberger M. A prospective study of antineutrophil cytoplasmic antibody (c\u2010ANCA) and clinical criteria in diagnosing Wegener's granulomatosis. Lancet1995;346:926\u201331.","DOI":"10.1016\/S0140-6736(95)91555-9"},{"key":"key\n\t\t\t\t20170703111748_R8","doi-asserted-by":"crossref","unstructured":"Hagen EC, Daha MR, Hermans J et al. Diagnostic value of standardized assays for anti\u2010neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC\/BCR Projects for ANCA Assay Standardization. Kidney Int1998;53:743\u201353.","DOI":"10.1046\/j.1523-1755.1998.00807.x"},{"key":"key\n\t\t\t\t20170703111748_R9","doi-asserted-by":"crossref","unstructured":"Dringenberg C, Apenberg S, Andrassy K. p\u2010ANCA with myeloperoxidase antibodies and c\u2010ANCA with proteinase 3 antibodies define a different vasculitis entity in patients with renal involvement. Adv Exp Med Biol1993;336:445\u20137.","DOI":"10.1007\/978-1-4757-9182-2_79"},{"key":"key\n\t\t\t\t20170703111748_R10","unstructured":"Geffriaud\u2010Ricouard C, Noel LH, Chauveau D, Houou S, Grunfeld JP, Lesavre P. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol1993;29:125\u201336."},{"key":"key\n\t\t\t\t20170703111748_R11","doi-asserted-by":"crossref","unstructured":"Franssen CF, Gans RO, Arends B et al. Differences between anti\u2010myeloperoxidase\u2010 and anti\u2010proteinase 3\u2010associated renal disease. Kidney Int1995;47:193\u20139.","DOI":"10.1038\/ki.1995.23"},{"key":"key\n\t\t\t\t20170703111748_R12","doi-asserted-by":"crossref","unstructured":"Franssen C, Gans R, Kallenberg C, Hageluken C, Hoorntje S. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti\u2010proteinase 3 and anti\u2010myeloperoxidase autoantibodies. J Intern Med1998;244:209\u201316.","DOI":"10.1046\/j.1365-2796.1998.00357.x"},{"key":"key\n\t\t\t\t20170703111748_R13","doi-asserted-by":"crossref","unstructured":"Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum1990;33:1101\u20137.","DOI":"10.1002\/art.1780330807"},{"key":"key\n\t\t\t\t20170703111748_R14","doi-asserted-by":"crossref","unstructured":"Jennette CJ, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum1994;37:187\u201392.","DOI":"10.1002\/art.1780370206"},{"key":"key\n\t\t\t\t20170703111748_R15","doi-asserted-by":"crossref","unstructured":"Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982;25:1271\u20137.","DOI":"10.1002\/art.1780251101"},{"key":"key\n\t\t\t\t20170703111748_R16","doi-asserted-by":"crossref","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum1988;31:315\u201324.","DOI":"10.1002\/art.1780310302"},{"key":"key\n\t\t\t\t20170703111748_R17","doi-asserted-by":"crossref","unstructured":"Wiik A, Rasmussen N, Wieslander J. Methods to detect autoantibodies to neutrophilic granulocytes. In: van Venrooij, WJ, Maini RN, eds. Manual of biological markers of disease. Dordrecht, Kluwer Academic Publishers, 1993;A9:1\u201314.","DOI":"10.1007\/978-94-011-5444-4_9"},{"key":"key\n\t\t\t\t20170703111748_R18","unstructured":"Hagen EC, Andrassy K, Csernok E et al. The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC\/BCR Group for ANCA Standardization. J Immunol Methods1993;159:1\u201316."},{"key":"key\n\t\t\t\t20170703111748_R19","doi-asserted-by":"crossref","unstructured":"Reinhold\u2010Keller E, Kekow J, Schnabel A et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum1994;37:919\u201324.","DOI":"10.1002\/art.1780370622"},{"key":"key\n\t\t\t\t20170703111748_R20","doi-asserted-by":"crossref","unstructured":"de Groot K, Gross WL. Wegener's granulomatosis: disease course, assessment of activity and extent and treatment. Lupus1998;7:285\u201391.","DOI":"10.1191\/096120398678920118"},{"key":"key\n\t\t\t\t20170703111748_R21","doi-asserted-by":"crossref","unstructured":"N\u00f6lle B, Specks U, L\u00fcdemann J, Rohrbach MS, DeRemee RA, Gross WL. Antineutrophil cytoplasmic antibodies: Their immunodiagnostic value in Wegener's granulomatosis. Ann Intern Med1989;111:28\u201340.","DOI":"10.7326\/0003-4819-111-1-28"},{"key":"key\n\t\t\t\t20170703111748_R22","doi-asserted-by":"crossref","unstructured":"Guillevin L, Durand\u2010Gasselin B, Cevallos R et al. Microscopic polyangiitis: clinical and laboratory findings in eighty\u2010five patients. Arthritis Rheum1999;42:421\u201330.","DOI":"10.1002\/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6"},{"key":"key\n\t\t\t\t20170703111748_R23","doi-asserted-by":"crossref","unstructured":"Kyndt X, Reumaux D, Bridoux F et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med1999; 106:527\u201333.","DOI":"10.1016\/S0002-9343(99)00064-9"},{"key":"key\n\t\t\t\t20170703111748_R24","doi-asserted-by":"crossref","unstructured":"Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg\u2013Strauss syndrome. Clinical study and long\u2010term follow\u2010up of 96 patients. Medicine1999; 78:26\u201337.","DOI":"10.1097\/00005792-199901000-00003"},{"key":"key\n\t\t\t\t20170703111748_R25","doi-asserted-by":"crossref","unstructured":"Schnabel A, Csernok E, Isenberg DA, Mrowka C, Gross WL. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Arthritis Rheum1995; 38:633\u20137.","DOI":"10.1002\/art.1780380509"},{"key":"key\n\t\t\t\t20170703111748_R26","unstructured":"Braun MG, Csernok E, Schmitt WH, Gross WL. Incidence, target antigens and clinical implications of antineutrophil cytoplasmic antibodies in rheumatoid arthritis. J Rheumatol1996;23:826\u201330."},{"key":"key\n\t\t\t\t20170703111748_R27","doi-asserted-by":"crossref","unstructured":"Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med1997;126:866\u201373.","DOI":"10.7326\/0003-4819-126-11-199706010-00003"},{"key":"key\n\t\t\t\t20170703111748_R28","doi-asserted-by":"crossref","unstructured":"Savige J, Gillis D, Benson E et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol1999;111:507\u201313.","DOI":"10.1093\/ajcp\/111.4.507"},{"key":"key\n\t\t\t\t20170703111748_R29","doi-asserted-by":"crossref","unstructured":"Wang G, Csernok E, de Groot K, Gross WL. Comparison of eight commercial kits for quantification of antineutrophil cytoplasmic antibodies (ANCA). J Immunol Methods1997;208:203\u201311.","DOI":"10.1016\/S0022-1759(97)00154-3"},{"key":"key\n\t\t\t\t20170703111748_R30","doi-asserted-by":"crossref","unstructured":"Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med1992;116:488\u201398.","DOI":"10.7326\/0003-4819-116-6-488"},{"key":"key\n\t\t\t\t20170703111748_R31","doi-asserted-by":"crossref","unstructured":"Franssen CF, Huitema MG, Muller Kobold AC et al. In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. J Am Soc Nephrol1999;10:1506\u201315.","DOI":"10.1681\/ASN.V1071506"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/40\/2\/178\/18095118\/400178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T16:37:38Z","timestamp":1621269458000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-lookup\/doi\/10.1093\/rheumatology\/40.2.178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2001,2]]},"published-print":{"date-parts":[[2001,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/40.2.178","relation":{},"ISSN":["1462-0332","1462-0324"],"issn-type":[{"value":"1462-0332","type":"electronic"},{"value":"1462-0324","type":"print"}],"subject":[],"published":{"date-parts":[[2001,2]]}}}